Sildenafil Reduces Insulin-Resistance in Human Endothelial Cells by Mammi, Caterina et al.
Sildenafil Reduces Insulin-Resistance in Human
Endothelial Cells
Caterina Mammi
1, Donatella Pastore
2, Marco F. Lombardo
2, Francesca Ferrelli
2, Massimiliano Caprio
1,
Claudia Consoli
3, Manfredi Tesauro
2, Lucia Gatta
3, Massimo Fini
3, Massimo Federici
2, Paolo Sbraccia
2,
Giulia Donadel
2, Alfonso Bellia
2, Giuseppe M. Rosano
3, Andrea Fabbri
2,4, Davide Lauro
2*
1Centre for Clinical and Basic Research, IRCCS San Raffaele Pisana, Rome, Italy, 2Department of Internal Medicine, University of Tor Vergata, Rome, Italy, 3San Raffaele
Sulmona, L’Aquila, Italy, 4Unit of Endocrinology, Department of Internal Medicine, Ospedale S. Eugenio and CTO A. Alesini, University of Tor Vergata, Rome, Italy
Abstract
Background: The efficacy of Phosphodiesterase 5 (PDE5) inhibitors to re-establish endothelial function is reduced in
diabetic patients. Recent evidences suggest that therapy with PDE5 inhibitors, i.e. sildenafil, may increase the expression of
nitric oxide synthase (NOS) proteins in the heart and cardiomyocytes. In this study we analyzed the effect of sildenafil on
endothelial cells in insulin resistance conditions in vitro.
Methodology/Principal Findings: Human umbilical vein endothelial cells (HUVECs) were treated with insulin in presence of
glucose 30 mM (HG) and glucosamine 10 mM (Gluc-N) with or without sildenafil. Insulin increased the expression of PDE5
and eNOS mRNA assayed by Real time-PCR. Cytofluorimetric analysis showed that sildenafil significantly increased NO
production in basal condition. This effect was partially inhibited by the PI3K inhibitor LY 294002 and completely inhibited by
the NOS inhibitor L-NAME. Akt-1 and eNOS activation was reduced in conditions mimicking insulin resistance and
completely restored by sildenafil treatment. Conversely sildenafil treatment can counteract this noxious effect by increasing
NO production through eNOS activation and reducing oxidative stress induced by hyperglycaemia and glucosamine.
Conclusions/Significance: These data indicate that sildenafil might improve NOS activity of endothelial cells in insulin
resistance conditions and suggest the potential therapeutic use of sildenafil for improving vascular function in diabetic
patients.
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Introduction
Nitric oxide (NO) is a reactive free radical gas acting as an
intracellular or extracellular messenger. It is synthesized from L-
arginine by a family of isoforms of NO synthases (NOS 1–3). NO
generation by NOS-3 (eNOS) in endothelial cells explains the
effects of endothelial-dependent vasodilators on vascular relaxa-
tion and decreased platelet adhesion and aggregation. These and
others effects of NO are mediated by increased cyclic GMP (c-
GMP) formation due to soluble guanylyl cyclase activation.
In turn c-GMP activates protein kinase G (PKG) and through
the phosphorylation of its substrates can regulate many other
biological processes. The increase of c-GMP is counteracted by
Phosphodiesterase 5 (PDE5) activity that transformes c-GMP into
GMP.
e-NOS activity is regulated by agonist-induced elevation of
intracellular free Ca
2+ concentration with subsequent binding of
Ca
2+/Calmodulin (Ca
2+/CaM) to e-NOS. However shear stress
and isometric contraction have been shown to activate the enzyme
in a Ca
2+/CaM-independent manner [1], through the activation
of c-GMP dependent PKG [2]. This mechanism may serve to
ensure continuous production of NO, independently of fluctua-
tions in intracellular Ca
2+ levels. Although eNOS was initially
reported to be phosphorylated exclusively on serine residues [3]
other evidence has shown that eNOS is also phosphorylated in
threonine- and tyrosine-domains [4]. NO production in endothe-
lial cells is regulated by phosphorylation of several eNOS
consensus sequence sites by means of protein kinase (PK) Akt-1,
PKC and calmodulin kinase II [5].
In addition to its well known metabolic action, insulin has
vasodilatory effects that depend on NO production in the vascular
endothelium. It has been demonstrated that e-NOS activation
induced by insulin is mediated by the PI3K-Akt pathway resulting
in e-NOS phosphorylation in Ser
1177 independently of Ca
2+-CaM
pathway [6]. Moreover insulin inhibition of PI3K/Akt-1 pathway
leads to impaired NO availability [7,8]. Reduced insulin-mediated
vasodilatation might contribute to vascular damage in insulin-
resistant states. We already demonstrated that hyperglycemia, via
hexosamine pathway activation, induces selective insulin resistance
in endothelial cells and impairs e-NOS activation [9].
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e14542Sildenafil citrate is a PDE5 inhibitor (PDE-5i) that belongs to
the ‘‘new class’’ of PDE-5i. PDE-5 selectively degrades cyclic
guanosine monophosphate (cGMP), hence its inhibition by
sildenafil raises cGMP intracellular levels inducing vasodilatation.
In recent years, several studies have shown that sildenafil initially
used for the treatment of erectile dysfunction, may have other
therapeutic applications [10–16]. Because of its potent vasodila-
tory action, sildenafil has also been extensively studied for treating
primary or hypoxia-induced pulmonary hypertension
[11,12,14,15,17].
Endothelial dysfunction is an important defect that contributes
to erectile dysfunction and vascular disease in diabetes and is
associated with insulin resistance [18]. It has been reported that
sildenafil can improve endothelial dysfunction after acute and
chronic treatment [19]. In diabetic rats PDE-5i (SK-3530) can
activate Akt-1 signaling and inhibit proapoptotic stimuli main-
taining erectile function [20].
A recent report showed that chronic treatment with sildenafil
improve glucose metabolism in a model of high-fat fed mice,
without directly affecting Akt-1 phosphorylation [21]. The
molecular mechanisms for these data still await demonstration; a
possible involvement of cGMP pathway in insulin signal
transduction could be hypothesized.
Since several reports have shown that endothelial dysfunction is
associated with insulin resistance [22–24], the aim of the present
study was to investigate the role of sildenafil in NO production and
changes in insulin signaling in HUVECs in basal and insulin
resistance conditions.
Methods
Materials
Human umbilical endothelial cells (HUVECs), human arterial
endothelial cells (HAEC) EBM-2 and EGM-2MV media were
purchased from Lonza (Walkersville, MD, USA). Human fetal
corpora cavernosa smooth muscle cells (hfCC) were a kind gift of
Prof. Mario Maggi. Phospho-Akt-1 (Ser-473 and Thr-308), Akt-1,
phospho eNOS (Ser-1177), eNOS and iNOS antibodies were
obtained from Cell Signaling (Waltham, Mass). TRIZOL, M-
MLV reverse transcriptase and Platinium High Fidelity Taq were
purchased from Invitrogen (Paisley, UK). BSA, Arginine, Glucose
and Glucosamine (Gluc-N) were obtained from Sigma (St Louis,
Mo). LY 294002, nitro-L-arginine methyl ester (L-NAME) a non
selective inhibitor of all NOS isoenzymes (26) and DAF-2DA were
purchased from Calbiochem (San Diego, CA). Sildenafil powder
was obtained from Viagra pills (Pfizer Inc); pills were ground into
Figure 1. PDE5 and iNOS expression in human endothelial cells. A: PDE5 mRNA expression in HUVEC and hfCC cells: RT-PCR shows that
HUVEC express detectable levels of PDE-5 mRNA. Actin was used as control. B: Western Blot analysis for PDE5 protein expression. C: Real time PCR
shows that insulin (30 min) and/or sildenafil (5 h) treatments induce PDE5 and eNOS but not iNOS expression *p,0.05 vs Ctrl, **p,0.01 vs Ctrl;
{ p,0.05 vs sildenafil. D: A representative Western Blot shows that insulin (30 min) and/or sildenafil (5 h) treatments do not alter iNOS protein levels.
doi:10.1371/journal.pone.0014542.g001
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filtered (0.45 mm pore size) and the solution was applied to a
285 mL Sephadex G-25 (superfine) column, equilibrated before
using in deionized H2Oa t2 0 uC [25]. Sildenafil was eluted with
500 mL of 1% formic acid, lyophilized and resuspended in
deionized H2O, and then was used to stimulate cell cultures. The
Sildenafil concentration of 1mM was chosen based on data from
Luedders et al. [26].
Cell culture
HUVEC and HAEC were growth in EGM-2MV at 37uCi na n
atmosphere of 95% air–5% CO2. HfCC were growth in M199
medium (Invitrogen) supplemented with 10% fetal bovine serum
(FBS, Invitrogen) and antibiotics (50 U of penicillin and 50 mgo f
streptomycin/ml). HUVEC and HAEC from passages 3 to 6 were
cultured for 72 hours in presence of 5.5 mmol/L glucose,
30 mmol/L glucose (high glucose; HG), 10 mmol/L Gluc-N with
or without 1 mM of sildenafil (5 or 72 h) and/or 10
27 M insulin.
LY 2940002 (30 mM) was used to block the PI3K and inhibit the
PI3K/Akt pathway.
RT-PCR analysis
The expression of endogenous PDE5 was determined by reverse
transcription (RT) of total RNA followed by PCR analysis. Total
RNA was extracted using TRIZOL. One microgram of total RNA
was reverse transcribed using M-MLV reverse transcriptase
according to the manufacturer’s protocol. PCR of the cDNA
was performed using Platinium High Fidelity Taq using the
following pairs of primers:
1. PDE5 sense: (59-39) ACC GCT ATT CCC TGT TCC TT
2. PDE5 antisense: (59-39) AAG GTC AAG CAG CAC CTG AT
PCR parameters were: 35 cycles (94uC for 45s, 58uC for 45s,
and 72uC for 1 min).
The PCR conditions were optimized for actin gene used as
control.
Real-Time Quantitative PCR
Single-stranded cDNA was synthesized from 4mg total RNA
samples using High-Capacity cDNA Archive Kit (Applied
Biosystems). cDNA (40 ng) was amplified by RT-PCR using ABI
PRISM 9700 System and TaqMan reagents. The 206Assays-on-
demand gene expression used were: PDE-5 (Hs00903251_m1),
iNOS (Hs00167248_m1), and eNOS (Hs00167166_m1). Human
RNA 18s were used for samples normalization. Each reaction was
carried out in triplicate.
Western Blot Analysis
Cells were incubated for four hours in EBM-2 additioned with
0,1% BSA. After starvation cells were incubated in EGM-2MV
with HG or with 10 mM Gluc-N to induce insulin resistance for
72 h with or without 1 mM sildenafil, added every 24 h. Cells were
treated with 100 nM insulin during the last 30 min. of incubation.
Extracts were obtained by lysing the cells in lysis buffer (50 mM
Tris-HCl pH 7.6, 100 mM NaCl, 2 mM EDTA, 1 mM MgCl2,
1 mM CaCl2, 1% Triton X-100, 10% glycerol, 100 mM NaF,
1 mM phenylmethylsulfonyl fluoride, 2 mM sodium ortovana-
date, 5 mM sodium pyrophosphate and protease inhibitor).
Protein concentration was determined by the method of Bradford,
using bovine serum albumin (BSA) as a standard. 100 mgo f
proteins from each lysate were separated on a 10% SDS/PAGE
gel and transferred to nitrocellulose membranes. Then membranes
were incubated with the following antibodies: anti-Akt-1, anti-
phospho Ser-473 Akt-1, anti-eNOS, anti-phospho Ser-1177
Figure 2. Akt-1 phosphorylation after sildenafil treatment. Insulin plus sildenafil treatment (1 mM/72 h) enhances Akt-1 phosphorylation in
insulin resistance condition respect to the same conditions without sildenafil. Full bars represent conditions without sildenafil, dashed bars represent
sildenafil treatment. Ctrl was expressed as 100%. Means 6 S.E. (n=5). { p,0.05 vs insulin; {p,0.05 vs HG+insulin; 1 p,0.05 vs Gluc-N+insulin.
doi:10.1371/journal.pone.0014542.g002
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horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG
secondary antibodies and enhanced chemiluminescence.
NO production determination
The FACScalibur (Fluorescent Activated Cell Sorting, Becton
Dickinson) was used to quantify NO production. Endothelial cells
were washed with PBS and starved for 1 h at 37uC in M199
phenol free medium plus 0.1% BSA. After 30 min. different
inhibitors were added when required (LY 294002 30 mM, L-
NAME 1 mM). Then 30 min. later sildenafil (1 mM) was
supplemented when demanded. Arginine (100 mM) was incubated
1h later and after 1h diaminofluoresceine-2 diacetate (DAF-2DA,
5 mM) probe was added. After 20 min. insulin (100 nM) has been
added for 1h. Finally endothelial cells were collected and analyzed
with FACS, by the Cellquest program (Becton Dickinson).
Statistical analysis of data
Data are representative of three or more independent
experiments. Results are reported as mean 6 SE or as percent
increase respect to control where appropriate. Differences between
treatments were analysed by ANOVA followed by Student’s test
and Mann Whitney test. A p value,0.05 was considered
significant.
Results
PDE5 expression in HUVECs
PDE-5 mRNA expression, measured in HUVECs cell line by
RT-PCR, was detectable compared to the expression in human
foetal corpora cavernosa (hfCC) cells used as positive control
(Fig. 1A). Furthermore, Western Blot studies showed a significant
expression of PDE-5 protein (Fig. 1B).
Insulin up-regulates eNOS and PDE5, whereas sildenafil
modulates only eNOS expression in HUVECs
Treatment with sildenafil (1 mM/5 h), insulin (100 nM/
30 min), alone and in combination induced a 2-fold increase of
eNOS but not iNOS mRNA expression, that remained roughly
unchanged after treatment. iNOS protein expression was also
unchanged in the same conditions (Fig. 1D). Interestingly, the
positive effect of sildenafil on eNOS expression was not amplified
by co-treatment with insulin. PDE-5 mRNA expression was up
regulated (,3 fold) by insulin alone or in combination with
sildenafil (,2.5 fold, Fig. 1C), whereas sildenafil alone did not
significantly modify it. These data show that in our cellular model
PDE5 expression is responsive to insulin treatment. Also, HUVEC
cells respond to sildenafil in terms of eNOS expression in
accordance with previous data, which showed that sildenafil
increases eNOS expression in pulmonary vessels [27].
Sildenafil increases Akt-1 phosphorylation in insulin-
resistance conditions
In order to validate our model of insulin resistance, we
measured Akt-1 Ser
473 phosphorylation in HUVECs cultured in
HG and Gluc-N for 72 h. In keeping with previous observations,
Akt-1 phosphorylation induced by insulin is impaired in HUVECs
exposed to HG (30 mM) or Gluc-N (10 mM) [28,29] respectively
of ,27% and ,37% (Figure 2). Interestingly, in the same
Figure 3. eNOS Ser
1177 phosphorylation after sildenafil treatment. Sildenafil chronic treatment (1 mM/72 h) enhances eNOS phosphorylation
in basal condition and after HG treatment, but not significantly after Gluc-N treatment. Full bars represent conditions without sildenafil, dashed bars
represent sildenafil treatment. Ctrl was expressed as 100%. Means 6 S.E. (n=5). *p,0.05 vs Ctrl, { p,0.05 vs insulin; { p,0.05 vs HG; {{ p,0.05 vs
HG + insulin.
doi:10.1371/journal.pone.0014542.g003
Sildenafil Effect in HUVECs
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stored the ability of insulin to stimulate Akt-1 phosphorylation in
presence of HG (+75% vs HG+insulin) or Gluc-N (+38% vs Gluc-
N+insulin).
Sildenafil improves eNOS Ser
1177 phosphorylation in
basal and in insulin-resistance conditions
Since eNOS is a downstream effector of Akt-1, we studied
eNOS Ser
1177 phosphorylation in the same conditions shown in
figure 2. Interestingly chronic (1 mM/72 h) and acute (1m M/5 h)
sildenafil treatment enhanced eNOS Ser
1177 phosphorylation by
,2 and 2.2 fold respectively (Fig. 3 and Fig. 4A) (p,0.05) under
basal conditions. Moreover eNOS phosphorylation induced by
acute sildenafil treatment is inhibited by LY294002 a PI3K
inhibitor (Figure 4A). In accordance with previous data [30], HG
reduced insulin induced eNOS Ser
1177 phosphorylation by 25%
(p,0.05). Sildenafil exposure (1 mM/72 h) markedly increased
eNOS phosphorylation in HG conditions, both in the absence
(+83% p,0.05) and in the presence (+74%, p,0.05) of insulin co-
treatment (Figure 3), differently from what observed for Akt-1
Ser
473 phosphorylation, where sildenafil was efficient only in the
presence of insulin. As expected, eNOS phosphorylation was
decreased by Gluc-N, in the presence of insulin (29%, p,0.05) and
co-treatment with sildenafil was unable to improve eNOS
phosphorylation, differently to what was observed for Akt-1
phosphorylation (Figure 3).
Treatment with sildenafil induces NO production, not
exclusively via PI3K pathway
In order to confirm that the increase in eNOS Ser
1177
phosphorylation induced by sildenafil displayed biological effects
in term of NO production, we studied intracellular generation of
NO by flow-cytometric analysis. Insulin (100 nM) stimulation for
1h induced a significant increase of NO production (p,0.05).
Sildenafil treatment (1 mM/5 h) markedly enhanced NO produc-
tion in HUVECs compared to control (p,0.01); such effect was
,1.5-fold higher than that obtained with insulin. Co-treatment
with insulin blunted the effect of sildenafil, probably because of the
insulin-induced increase in PDE-5 expression, previously de-
scribed in fig. 1. In order to evaluate if sildenafil effects were
mediated by PI3K pathway, the same experiments were
performed in the presence of LY294002, a PI3K inhibitor. LY
Figure 4. eNOS Ser
1177 phosphorylation and NO production induced by acute treatment with sildenafil. A: Western Blot analysis of
eNOS Ser
1177 phosphorylation. Means 6 S.E. (n=4). * p,0.05 vs Ctrl; u p,0.05 vs insulin; **p,0.01 vs sildenafil; uup,0.05 vs sildenafil+insulin. B:
Sildenafil treatment (1 mM/5 h) induces NO production that is partially inhibited from LY. Means 6 S.E. (n=6). *p,0.05 vs Ctrl; **p,0.01 vs Ctrl;
{ p,0.05 vs insulin; " p,0.05 vs LY; "" p,0.05 vs LY+insulin; # p,0.05 and ## p,0.01 vs sildenafil; I p,0.05 vs sildenafil+insulin. C: L-NAME effects
on NO production induced by sildenafil treatment. L-NAME reduces NO production induced by acute treatment with sildenafil. Means 6 S.E. (n=6).
*p,0.05 vs Ctrl; # p,0.05 vs sildenafil. Full bar represent conditions without sildenafil, dashed bars represent sildenafil treatment.
doi:10.1371/journal.pone.0014542.g004
Sildenafil Effect in HUVECs
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(p,0.05), as expected [31]. In the absence of insulin LY markedly
blunted sildenafil-induced NO production (p,0.01). However, LY
did not completely reverse the effect of sildenafil since NO levels
were not reduced to the baseline levels. These data suggest that in
our model sildenafil effects are not mediated only through the
PI3K pathway (Figure 4B).
In order to confirm whether NO generation induced by
sildenafil was due to eNOS activation, NO production studies
were repeated in the presence of L-NAME, a NOS inhibitor. As
expected, L-NAME treatment completely reversed to baseline
levels both insulin- (data not shown) and sildenafil-induced NO
generation (1mM/5h). (Figure 4 C). These results were confirmed
also in HAEC (data not shown).
Figure 5. NO production in insulin-resistance conditions after sildenafil treatment. Sildenafil treatment induces NO production in insulin
resistance condition (HG and Gluc-N) in HUVEC (panel A) and HAEC (panel B). Full bars represent conditions without sildenafil, dashed bars represent
sildenafil treatment. Means 6 S.E. (n=6). *p,0.05 and **p,0.01 vs Ctrl; { p,0.05 and {{ p,0.01 vs insulin; { p,0.05 vs HG; $ p,0.05 vs sildenafil;
# p,0.05 vs sildenafil+HG; ‘ p,0.05 vs Gluc-N.
doi:10.1371/journal.pone.0014542.g005
Sildenafil Effect in HUVECs
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presence of sildenafil
As already established [7,8], in accordance with eNOS
phosphorylation studies (figure 3), conditions simulating insulin
resistance (HG and Gluc-N) markedly inhibited NO production
induced by insulin in HUVECs (p,0.05). Sildenafil treatment
(1 mM/72 h) significantly increased NO generation, both in the
presence of HG (p,0.05) and Gluc-N (p,0.05). Moreover insulin
blunted sildenafil-induced increase in NO generation under insulin
resistance conditions. Such effect was significant in HG conditions
(p,0.05), but did not reach statistical significance with Gluc-N
(Figure 5A). Similar data were obtained in HAEC (Figure 5B).
Discussion
The present study confirms that HUVECs express PDE5
mRNA as previously reported [32] and shows for the first time
that its expression is regulated by insulin. HUVECs acute
treatment (5 h) with sildenafil induced a sharp increase in NO
production independently of insulin stimulation. Furthermore,
sildenafil was able to reverse the suppression in insulin-induced
NO production, caused by the PI3-K inhibitor LY294002. Pre-
treatment with L-NAME, a NOS inhibitor, completely blocks the
burst of NO production induced by sildenafil, claiming for a NOS-
dependent effect. Chronic treatment with sildenafil (72 h)
increased NO production both in basal conditions as well as in
insulin resistance conditions.
It is well known that insulin promotes vasodilation and increases
blood flow by modulating eNOS activity and expression through
activation of the PI3-K/Akt-1 signalling [8,33]. As expected [9]
insulin stimulation induced NO production in HUVECs and
inhibition of PI3K pathway by LY294002 reduced insulin-
stimulated NO production. Our results show for the first time
that in endothelial cells sildenafil enhances NO production by
PDE5 inhibition and eNOS activation through a PI3K dependent
pathway. We hypothesize that sildenafil, through specific inhibi-
tion of PDE-5, could increase intracellular concentration of free
Ca
2+ by c-GMP. Moreover it is possible that sildenafil increases
intracellular Ca
2+ levels in a cGMP independent manner by
activating K
+ channels with large conductance (BKCa) [26]. It is
known that the association of Ca
2+/calmodulin complex with
eNOS increases eNOS Ser
1177 phosphorylation and decreases
Thr
495 dephosphorylation [34]. This mechanism could amplify
NO production in response to the intracellular Ca
2+ elevation.
Our results show that sildenafil does not enhance Akt-1
phosphorylation in basal conditions, although Akt-1 Ser
473pho-
sphorylation has been shown to increase after sildenafil stimulation
in striatal [35] and corpora cavernosa smooth muscle (20).
Sildenafil differently, increases Akt-1 Ser
473 phosphorylation in
HUVECs when associated with insulin co-treatment in presence of
higher oxidative stress levels (HG and Gluc-N), improving insulin
action. These data are in accordance with previous studies
demonstrating that sildenafil decreases ROS and nitrotyrosine cell
production [36,37]. Interestingly, in basal conditions sildenafil
increased NO production without modifying Akt-1 phosphoryla-
tion (Fig. 2 and 3). Such effect was only partially reversed by PI3K
inhibitor LY, without reaching baseline levels. This suggests a
partial involvement of PI3K in the observed effect, whereas we can
exclude the involvement of Akt-1 phosphorylation. It is possible
that PI3K activates eNOS by modulating other kinases like
Figure 6. Schematic summary of sildenafil action in endothelial cells.
doi:10.1371/journal.pone.0014542.g006
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effects are insulin-independent. These data are in accordance with
a work of Ayala, who found that in mice with an high fat diet
sildenafil improved insulin sensitivity measured with hyperinsulin-
emic-euglycemic clamp with no increased levels of Akt-1
phosphorylation [21].
Hyperglycaemic impairment of nitric oxide (NO) production by
endothelial cells is implicated in the effect of diabetes to increase
cardiovascular disease risk. As already reported [38,39], we found
that in insulin resistance conditions, insulin treatment does not
induce NO production; chronic treatment with sildenafil improves
NO production in basal conditions as well as in insulin resistance
conditions in e-NOS-dependent manner. This effect was reduced
when insulin resistance was induced by Gluc-N. In these
conditions, the positive effect of sildenafil on eNOS phosphory-
lation was completely inhibited by Gluc-N. However eNOS
mediated NO production was partly restored even in presence of
Gluc-N. These results could be explained by the different
mechanism of glucotoxicity. In fact, it is known that Gluc-N, by
activating hexosamine pathway, causes O-GlcNac modifications at
protein sites which are involved in insulin signalling [40].
Interestingly, under insulin resistance conditions we observed that
insulin blunted the increase in NO generation induced by
sildenafil. We demonstrated that insulin treatment was able to
up-regulate PDE5 mRNA expression in HUVEC. It is possible
that insulin increased PDE-5 mRNA expression through the
transcription factors Sp1, AP-1 and AP-2. Indeed, AP-1 consensus
sequence has been located at – 485 from the starting PDE-5 gene
expression sequence (http://variome.kobic.re.kr/SNPatPromoter/
snpatpromoter.jsp?id=NM_001083).
As a consequence, it is possible that insulin might reduce
intracellular cGMP through an increased activity of PDE5, with a
consequent decrease in Ca
2+/CaM dependent eNOS activation
and subsequent NO production.
These findings indicate that sildenafil improves insulin signalling
and NO production in endothelial cells, probably by reducing
oxidative stress induced by hyperglycemia and by increasing
intracellular Ca
2+ levels.
The novel finding that insulin stimulates PDE-5 expression can
explain the reduced response to sildenafil therapy in diabetic
patients with elevated insulin resistance and hyperinsulinemia.
Our data clarify the mechanism through which sildenafil improves
insulin action in endothelial cells. Further investigation are
necessary to discover all the substrates involved in this process
and to understand if this novel action of sildenafil is specific for this
molecule or it is a class effect of PDE-5i.
In conclusion, we hypothesize that sildenafil can be potentially
used to improve insulin action in type 2 diabetic patients leading to
new therapeutic strategies for type 2 diabetes and other related
cardiovascular disease.
In Figure 6 we show a schematic summary of sildenafil action in
endothelium.
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